Merck & Co. ended a partnership with Addex Pharmaceuticals involving the latter's positive allosteric modulators of metabotropic glutamate receptor 4 to treat Parkinson's disease. The licensing deal was formed in 2007 and worth at least $106.5 million in milestone fees. Addex remains committed to developing the compounds for Parkinson's and other indications, said CEO Bharatt Chowrira.

Full Story:
PharmaTimes (U.K.)

Related Summaries